FibroBiologics (FBLG) Competitors $2.15 -0.01 (-0.46%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends FBLG vs. IMMP, LRMR, CMPS, ACIU, BNTC, AMLX, LFCR, ITOS, FHTX, and ELDNShould you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Immutep (IMMP), Larimar Therapeutics (LRMR), COMPASS Pathways (CMPS), AC Immune (ACIU), Benitec Biopharma (BNTC), Amylyx Pharmaceuticals (AMLX), Lifecore Biomedical (LFCR), iTeos Therapeutics (ITOS), Foghorn Therapeutics (FHTX), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. FibroBiologics vs. Immutep Larimar Therapeutics COMPASS Pathways AC Immune Benitec Biopharma Amylyx Pharmaceuticals Lifecore Biomedical iTeos Therapeutics Foghorn Therapeutics Eledon Pharmaceuticals FibroBiologics (NASDAQ:FBLG) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, community ranking, media sentiment, risk, dividends and valuation. Does the MarketBeat Community prefer FBLG or IMMP? Immutep received 306 more outperform votes than FibroBiologics when rated by MarketBeat users. However, 100.00% of users gave FibroBiologics an outperform vote while only 72.56% of users gave Immutep an outperform vote. CompanyUnderperformOutperformFibroBiologicsOutperform Votes6100.00% Underperform VotesNo VotesImmutepOutperform Votes31272.56% Underperform Votes11827.44% Do insiders & institutionals have more ownership in FBLG or IMMP? 2.3% of Immutep shares are owned by institutional investors. 20.8% of FibroBiologics shares are owned by company insiders. Comparatively, 3.1% of Immutep shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is FBLG or IMMP more profitable? Company Net Margins Return on Equity Return on Assets FibroBiologicsN/A N/A -225.34% Immutep N/A N/A N/A Do analysts recommend FBLG or IMMP? FibroBiologics currently has a consensus target price of $13.00, indicating a potential upside of 504.65%. Immutep has a consensus target price of $8.50, indicating a potential upside of 299.06%. Given FibroBiologics' stronger consensus rating and higher probable upside, equities analysts plainly believe FibroBiologics is more favorable than Immutep.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Immutep 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer FBLG or IMMP? In the previous week, FibroBiologics and FibroBiologics both had 7 articles in the media. FibroBiologics' average media sentiment score of 0.55 beat Immutep's score of 0.36 indicating that FibroBiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immutep 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, FBLG or IMMP? FibroBiologics has higher earnings, but lower revenue than Immutep. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroBiologicsN/AN/A-$16.49MN/AN/AImmutep$5.14M60.28-$28.01MN/AN/A SummaryFibroBiologics beats Immutep on 8 of the 12 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get FibroBiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBLG vs. The Competition Export to ExcelMetricFibroBiologicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.52M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E RatioN/A10.75135.1817.54Price / SalesN/A287.861,228.03140.34Price / CashN/A56.6540.6537.95Price / Book53.755.394.884.92Net Income-$16.49M$152.04M$118.97M$225.78M7 Day Performance-6.11%-4.32%15.73%-1.58%1 Month Performance-14.17%2.80%15.69%6.67%1 Year PerformanceN/A17.30%34.73%22.48% FibroBiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBLGFibroBiologics1.6988 of 5 stars$2.15-0.5%$13.00+504.7%N/A$74.52MN/A0.0010Short Interest ↑IMMPImmutep1.5604 of 5 stars$2.04-6.4%$8.50+316.7%-14.5%$296.74M$5.14M0.002,021News CoverageGap UpLRMRLarimar Therapeutics1.9737 of 5 stars$4.65-24.6%$20.43+339.3%+2.4%$296.72MN/A-3.5630Analyst ForecastNews CoverageGap DownHigh Trading VolumeCMPSCOMPASS Pathways2.9382 of 5 stars$4.32+2.4%$33.60+677.8%-47.5%$295.58MN/A-1.92120Short Interest ↓Positive NewsACIUAC Immune2.6486 of 5 stars$2.94-0.3%$12.00+308.2%-25.0%$290.88M$16.48M-6.41140Positive NewsBNTCBenitec Biopharma3.6559 of 5 stars$12.52+6.4%$24.43+95.1%+278.9%$290.71M$80,000.000.0020Analyst ForecastShort Interest ↑AMLXAmylyx Pharmaceuticals4.2863 of 5 stars$4.18+1.5%$7.33+75.4%-69.9%$286.53M$196.49M-1.08200Short Interest ↓News CoverageLFCRLifecore Biomedical3.6897 of 5 stars$7.72+1.4%$10.00+29.5%+27.7%$284.30M$128.44M97.50690ITOSiTeos Therapeutics3.5971 of 5 stars$7.74+0.8%$25.25+226.2%-29.1%$282.77M$35M-2.4490FHTXFoghorn Therapeutics2.9771 of 5 stars$5.02-5.3%$16.00+218.7%+4.2%$279.08M$25.52M-2.63120Analyst ForecastShort Interest ↓News CoverageGap DownHigh Trading VolumeELDNEledon Pharmaceuticals3.1299 of 5 stars$4.51+3.0%$16.00+254.8%+196.1%$269.43MN/A-2.3310Short Interest ↓Positive NewsHigh Trading Volume Related Companies and Tools Related Companies IMMP Competitors LRMR Competitors CMPS Competitors ACIU Competitors BNTC Competitors AMLX Competitors LFCR Competitors ITOS Competitors FHTX Competitors ELDN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FBLG) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
